Taiwan Advance Bio-Pharmaceutical, Inc. engages in the research, development, production, and sale of drug residue testing reagents. It operates through the following business segments: Inspection business, Food safety, Precision medicine, Research and development unit 2, and New business. The Inspection business segment offers drug abuse certification testing services. The Food safety segment offers drug residue detection reagents. The Precision medicine segment provides cord blood preservation as well as testing and cord blood gene related customer services. The Research and development unit 2 segment includes the development of new drugs and hematopoietic stem cell proliferation technology. The New business segment offers genetic testing and business services. The company was founded on May 25, 2000 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company